research
A scientist’s opinion : Interview with Prof Cristina Mussini about covid-19 treatment
Interview with Professor Cristina Mussini, Head of the Department of Infectious Diseases and Tropical Medicine at the University of Modena and Reggio Emilia in Italy and member of the European AIDS Clinical Society. She has been actively involved in various recent studies on the clinical use of tocilizumab in patients with COVID-19 pneumonia. First a ...
A scientist’s opinion : Interview with Dr Andrew Ip about covid-19 treatment
Interview with Dr Andrew Ip, a specialist in hematology/oncology at the John Theurer Cancer Center at Hackensack University Medical Center, USA, who has been involved in research on tocilizumab use in COVID-19 patients. Why did you choose tocilizumab to treat patients with COVID-19 pneumonia? Andrew Ip: Tocilizumab is a monoclonal antibody that inhibits the interleukin-6 ...
A scientist’s opinion : Interview with Dr Juan Victor San-Martin Lopez about covid-19 treatment
Interview with Dr Juan Victor San-Martín López, a physician specialising in infectious diseases and a member of the task force coordinating responses to the leishmaniasis outbreak in 2011 and to COVID-19 at the Hospital Universitario de Fuenlabrada, Spain. He reports on his experience with tocilizumab use in COVID-19 patients. What is the so-called cytokine storm? ...
The key role of antivirals in COVID-19 treatment (remdesivir)
A few weeks after the SARS-CoV-2 was identified by Chinese researchers as the cause of ‘COVID-19’, an antiviral called remdesivir, originally used during the 2014 Ebola outbreak, came into play as the first available option to treat patients with coronavirus disease 2019 (COVID-19). Even if the approval process for remdesivir caused some controversy, experts consider the combined use of antivirals and other drugs a promising solution for treatment of Covid-19.
A scientist’s opinion : Interview with Prof Martijn van Hemert about covid-19 treatment
Interview with Martijn van Hemert, Associate professor and Principal Investigator in molecular virology and antiviral strategies at the Leiden University Medical Center. In recent years, his group has mainly been studying the Chikungunya and Zika viruses, but in the past he has also studied SARS-CoV. Since February 2020, he has shifted his focus to research ...
A scientist’s opinion : Interview with Dr Juan Pablo Horcajada about covid-19 treatment
Interview with Juan Pablo Horcajada, MD. is Head of the Department of Infectious Diseases and General Coordinator of the COVID-19 Service at the Hospital del Mar, Barcelona. Remdesivir is the first drug approved by the EMA to be used as part of the treatment of COVID-19 patients. How’s the use of this antiviral in your ...
ESMH Press Review – October 7, 2020
Conspiracy theoris, Green Deal & research integrity: check out the ESMH selection of 16 science & tech news published in the last weeks on the web. Pick your favourite from the most popular topics in the mainstream media!
What drives public trust in science-based policies? Ask PEriTiA
A multinational EU research project will review the role of science in policy decision-making using climate change as a proxy with the aim of establishing public trust. We live in complex times. Times when the opinion of uninformed sources in social media seems to have a stronger influence than expert voices. And if this is ...
